Cargando…
Targeting targeted agents: open issues for clinical trial design
Molecularly targeted agents for the treatment of solid tumors had entered the market in the last 5 years, with a great impact upon both the scientific community and the society. Many randomized phase III trials conducted in recent years with new targeted agents, despite previous data coming from pre...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697149/ https://www.ncbi.nlm.nih.gov/pubmed/19463172 http://dx.doi.org/10.1186/1756-9966-28-66 |